Accolade (NASDAQ:ACCD) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Accolade (NASDAQ:ACCD) released its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01, Briefing.com reports. Accolade had a negative return on equity of 22.57% and a negative net margin of 24.09%. The business had revenue of $124.80 million for the quarter, compared to the consensus estimate of $123.91 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. Accolade’s quarterly revenue was up 26.1% on a year-over-year basis. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Performance

Shares of ACCD stock traded down $1.30 on Friday, hitting $7.89. The company’s stock had a trading volume of 1,491,193 shares, compared to its average volume of 585,879. Accolade has a fifty-two week low of $6.33 and a fifty-two week high of $17.00. The company has a market capitalization of $610.76 million, a PE ratio of -5.93 and a beta of 2.08. The stock’s 50 day moving average is $9.66 and its 200-day moving average is $9.91. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.35 and a current ratio of 2.35.

Analyst Upgrades and Downgrades

ACCD has been the topic of a number of analyst reports. Morgan Stanley dropped their price objective on Accolade from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Friday. SVB Leerink assumed coverage on shares of Accolade in a research note on Monday, February 26th. They issued an “outperform” rating and a $16.00 price target for the company. Canaccord Genuity Group decreased their price objective on shares of Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday. Stifel Nicolaus cut their target price on shares of Accolade from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Finally, Piper Sandler lifted their price target on Accolade from $12.00 to $15.00 and gave the stock an “overweight” rating in a report on Tuesday, January 9th. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.80.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.